A Study of GW685698X in Healthy Japanese Male Subjects

NCT00972673 | Completed Phase 1

• 1 other identifier: 112018
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects.

Conditions

Asthma

Outcome Measures

Primary Outcomes (3)

• safety: adverse events, vital sign, ECGs, and clinical laboratory test

• PK： Cmax, tmax and AUC(0-t)

• PD: serum cortisol

Study Arms (2)

arm 1

EXPERIMENTAL

In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.

Drug: GW685698X

arm 2

PLACEBO COMPARATOR

In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.

Drug: Placebo

Interventions

Placebo DRUG

comparator

arm 2

GW685698X DRUG

Inhaled steroid

arm 1

Eligibility Criteria

• Age: 20 Years - 64 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory studies, and other tests.
• Body weight ≥ 50kg and BMI within the range 18.5-25.0kg/m2 inclusive.
• Non-smokers (never smoked or not smoking for \>6 months with \<10 pack years history (Pack years = (cigarettes per day smoked/20) x number of years smoked))
• Clinical laboratory tests data obtained at screening meet the following:
• AST(GOT), ALT(GPT), total-bilirubin: below the upper limit of the normal ranges
• Normal 12-lead EGC finding at screening; QTc(B) interval \<450msec
• Normal spirometry (FEV1 ≥ 80% of predicted, FEV1/FVC ≥ 70%).
• Rapid ACTH with normal range at the screening.
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• Capable of using the novel dry powder inhaler.

You may not qualify if:

• The subject has an allergy for any drug or idiosyncrasy
• The subject has an allergy for any drug hypersensitivity to milk protein or the excipients lactose monohydrate and magnesium stearate.
• T he subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
• The subject has participated in a clinical study with an investigational or a non-investigational drug or device during the previous 4 months.
• The subject has a history or current conditions of drug abuse or alcoholism.
• History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink = 5 ounces (150mL) of wine or 350mL of beer or 1.5 ounces (45mL) of 80 proof distilled spirits) within 6 month of screening.
• The subject is positive for urine drug at screening.
• Use of prescription or non-prescription drugs, including CYP3A/PGP inhibitor, vitamins, herbal and dietary supplements (including St John'sWort) within 14 days prior to the first dose of study medication.
• The subject has a known allergy or hypersensitivity to corticosteroids.
• The subject has a known allergy or hypersensitivity to synthetic ACTH
• The subject has a history of asthma in childhood or respiratory disorder.
• The subject is a permanent (or occasional during the study) night-shift worker\*.
• \* Permanent night shift worker defines as the person who has been continuing life that gets up after 12:00 day time and eats supper after 0:00 midnight for seven days or more usually.
• The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody.
• The subject has donated a unit of blood "\>400mL" within the previous 4 months or "\>200mL" within the previous 1 month.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Kagoshima, 890-0081, Japan

Location

Related Publications (1)

• Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, Hirama T. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Int J Clin Pharmacol Ther. 2013 Aug;51(8):660-71. doi: 10.5414/CP201822.

  PMID: 23735179 BACKGROUND

Related Links

• Results for study 112018 can be found on the GSK Clinical Study Register.
• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 3, 2009
• First Posted: September 7, 2009
• Study Start: September 24, 2008
• Primary Completion: December 19, 2008
• Study Completion: December 19, 2008
• Last Updated: August 3, 2017

Record last verified: 2017-08

Data Sharing

• IPD Sharing: Will share

Locations

JP (1)